NRx Pharmaceuticals announces plan to regain compliance with Nasdaq

NRx Pharmaceuticals announced an update on plans to achieve compliance with Nasdaq market requirements related to minimum bid price and total Market Value of Listed Securities, or MVLS. As has been previously disclosed, Nasdaq presented NRx with two deficiency notices, one related to failure to maintain the minimum $1 bid price and the other related to failure to maintain the minimum MVLS for the Nasdaq Global Market. Because there were two simultaneous deficiencies, the company did not qualify for a second automatic 180-day compliance period on the bid price deficiency.